
The study was conducted to assess the potential of using desmopressin to reduce the risk of death in patients with the spontaneous intracerebral haemorrhage who are taking antiplatelet drugs. The study involved 54 participants, with half receiving desmopressin and the other half receiving a placebo. The trial showed that it is feasible to randomize such patients for this treatment. While there were no significant withdrawals, adverse events were observed in both groups.
Like
Save
Share